MyOme Joins Mayo Clinic Platform_Accelerate Cohort to Advance Preventative Care

Access to De-Identified Clinical Data Will Help MyOme Scale Its Artificial Intelligence Solutions

MENLO PARK, Calif., Aug. 12, 2025 /PRNewswire/ -- MyOme, Inc, a leader in whole-genome analysis and polygenic risk scores, today announced its entry into Mayo Clinic Platform_Accelerate, an initiative that supports healthcare innovators to validate and scale artificial intelligence (AI) based solutions using rich, de-identified clinical data sets.

As a member of the Mayo Clinic Platform_Accelerate cohort, MyOme will apply its Integrated Risk Models (IRMs) technology that combines whole-genome sequencing, polygenic risk scores (PRS), and AI analysis of clinical data to identify people at heightened risk for common conditions including cardiometabolic diseases and cancers. The work supports an overarching mission to shift healthcare from reactive to proactive care.

Through the program, MyOme will:

• Validate and improve IRM performance across over 20 rare and common conditions by leveraging rich, longitudinal five-year de-identified dataset of ~3M patients.
• Incorporate its deep-learning-based techniques to boost risk prediction accuracy and timeliness, helping to surface risk years before disease manifestation–at the time when disease can be prevented or onset delayed.
• Generate evidence to support reimbursement pathways to drive equitable access to genomics-based screening.

"As part of the Mayo Clinic_Platform Accelerate cohort, we will gain access to high quality clinical data, giving us an ideal springboard to refine our next-generation of integrated risk models (IRMs) that combine deep medical histories and genomics," said Akash Kumar, MD, PhD, Chief Medical and Science Officer at MyOme. "Our motivation is simple—more accurate risk assessments, targeted interventions, and longer, healthier lives for the patients we serve".

MyOme operates a CLIA-certified and CAP-accredited laboratory and offers end-to-end clinical workflows for physicians and their patients. MyOme's Proactive Health Report includes single-gene risk analysis, a medication response report, and various IRMs. In March 2025, MyOme launched its first whole-genome-based diagnostic test for rare disease.

Learn more about Mayo Clinic Platform_Accelerate: https://www.mayoclinicplatform.org/accelerate/#program-details

About MyOme
MyOme^® is a clinical whole-genome analysis company helping individuals and families understand their risk for inherited disease. As a leader in polygenic risk modeling, MyOme delivers lifetime insights through a single whole-genome test. CLIA- and CAP-certified, MyOme is headquartered in Menlo Park, California. Learn more at www.myome.com.

SOURCE MyOme, Inc